Hims & Hers will sell a compounded version of the new Wegovy pill for a fraction of the price, claiming a legal workaround to U.S. patent protection. Novo Nordisk’s stock dove 7% on Thursday just after an announcement from a key competitor.
Hims & Hers will sell a compounded version of the new Wegovy pill for a fraction of the price, claiming a legal workaround to U.S. patent protection. Novo Nordisk’s stock dove 7% on Thursday just after an announcement from a key competitor.